The aberrant activation of the FGFR signaling is detected in many solid tumors, including
pancreatic ductal adenocarcinoma (PDAC), suggesting it as a potential therapeutic target. In …

Pancreatic adenocarcinoma (PDAC) is projected to become the second leading cause of
cancer deaths by 2030, and its five-year survival is 12%(Rahib et al., 2014; Siegel, Miller …

Pancreatic cancer is regarded as the most lethal solid tumor worldwide. Deregulated and
constitutively activated NF-κB signaling is one of the major characteristics of pancreatic …

Background: Fibroblast growth factor receptor (FGFR) signalling has been implicated in
pancreas carcinogenesis. We investigated the effect of FGFR inhibition in pancreatic cancer …

Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis with a 5 year survival rate
of less than 8%, and is predicted to become the second leading cause of cancer-related …

In pancreatic ductal adenocarcinoma (PDAC), the fibroblast growth factor receptor 1 (FGFR-
1) IIIb isoform correlates with the inhibition of cancer cell proliferation, migration, and …

Background The clinical significance of fibroblast growth factor receptor 1 (FGFR1) protein
expression in pancreatic cancer is largely unknown. In this study, we aimed investigate the …

Transcriptomic analyses of pancreatic ductal adenocarcinoma (PDAC) have identified two
major epithelial subtypes with distinct biology and clinical behaviours. Here, we aimed to …

Effective therapies are limited for pancreatic cancer, particularly for those with distant tumour
metastases. Therefore, more individualised drug screening is urgently required. Next …

Recently, fibroblast growth factors are identified to play a vital role in the development and
progression of human pancreatic cancer. FGF pathway is critical involved in numerous …